When deciding between chemo-immunotherapy vs immunotherapy alone for metastatic NSCLC, do you ever consider CPS (Combined positive score) in addition to TPS which was utilized in all lung studies?

Community
Company
News
Contact Us
Sign in

Topics: Thoracic Malignancies • Medical Oncology

CPS is utilized in other cancers, do we know any role in NSCLC?

Related Questions

What is your approach for an RA patient with lung cancer who is starting immunotherapy?

Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?

Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?

Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?

Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?

How would you treat patients with limited-stage small cell lung cancer who have short term contraindications for systemic chemotherapy?

For patients with biphasic mesothelioma who complete pleurectomy/decortication, would you consider offering adjuvant combination immune checkpoint inhibitor therapy vs. platinum chemotherapy?

In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?

Would you offer empiric radiation for a growing mediastinal mass radiographically suspicious for thymoma in a patient who declines surgery?